385 related articles for article (PubMed ID: 32120135)
1. WEE1 kinase limits CDK activities to safeguard DNA replication and mitotic entry.
Elbæk CR; Petrosius V; Sørensen CS
Mutat Res; 2020; 819-820():111694. PubMed ID: 32120135
[TBL] [Abstract][Full Text] [Related]
2. Mitotic progression becomes irreversible in prometaphase and collapses when Wee1 and Cdc25 are inhibited.
Potapova TA; Sivakumar S; Flynn JN; Li R; Gorbsky GJ
Mol Biol Cell; 2011 Apr; 22(8):1191-206. PubMed ID: 21325631
[TBL] [Abstract][Full Text] [Related]
3. Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading.
Hauge S; Naucke C; Hasvold G; Joel M; Rødland GE; Juzenas P; Stokke T; Syljuåsen RG
Oncotarget; 2017 Feb; 8(7):10966-10979. PubMed ID: 28030798
[TBL] [Abstract][Full Text] [Related]
4. Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer.
Geenen JJJ; Schellens JHM
Clin Cancer Res; 2017 Aug; 23(16):4540-4544. PubMed ID: 28442503
[TBL] [Abstract][Full Text] [Related]
5. WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe.
De Witt Hamer PC; Mir SE; Noske D; Van Noorden CJ; Würdinger T
Clin Cancer Res; 2011 Jul; 17(13):4200-7. PubMed ID: 21562035
[TBL] [Abstract][Full Text] [Related]
6. Cytokinetic effects of Wee1 disruption in pancreatic cancer.
Chang Q; Chandrashekhar M; Ketela T; Fedyshyn Y; Moffat J; Hedley D
Cell Cycle; 2016; 15(4):593-604. PubMed ID: 26890070
[TBL] [Abstract][Full Text] [Related]
7. Targeting WEE1 Kinase in Cancer.
Matheson CJ; Backos DS; Reigan P
Trends Pharmacol Sci; 2016 Oct; 37(10):872-881. PubMed ID: 27427153
[TBL] [Abstract][Full Text] [Related]
8. Differential properties of mitosis-associated events following CHK1 and WEE1 inhibitor treatments in human tongue carcinoma cells.
Nojima H; Homma H; Onozato Y; Kaida A; Harada H; Miura M
Exp Cell Res; 2020 Jan; 386(2):111720. PubMed ID: 31738907
[TBL] [Abstract][Full Text] [Related]
9. Two Distinct Cdc2 Pools Regulate Cell Cycle Progression and the DNA Damage Response in the Fission Yeast S.pombe.
Caspari T; Hilditch V
PLoS One; 2015; 10(7):e0130748. PubMed ID: 26131711
[TBL] [Abstract][Full Text] [Related]
10. DNA repair factor RAD18 and DNA polymerase Polκ confer tolerance of oncogenic DNA replication stress.
Yang Y; Gao Y; Mutter-Rottmayer L; Zlatanou A; Durando M; Ding W; Wyatt D; Ramsden D; Tanoue Y; Tateishi S; Vaziri C
J Cell Biol; 2017 Oct; 216(10):3097-3115. PubMed ID: 28835467
[TBL] [Abstract][Full Text] [Related]
11. Wee1 kinase as a target for cancer therapy.
Do K; Doroshow JH; Kummar S
Cell Cycle; 2013 Oct; 12(19):3159-64. PubMed ID: 24013427
[TBL] [Abstract][Full Text] [Related]
12. A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target.
Ghelli Luserna di Rorà A; Cerchione C; Martinelli G; Simonetti G
J Hematol Oncol; 2020 Sep; 13(1):126. PubMed ID: 32958072
[TBL] [Abstract][Full Text] [Related]
13. Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine.
Garcia TB; Fosmire SP; Porter CC
Leuk Res; 2018 Jan; 64():30-33. PubMed ID: 29175378
[TBL] [Abstract][Full Text] [Related]
14. Premature activation of Cdk1 leads to mitotic events in S phase and embryonic lethality.
Szmyd R; Niska-Blakie J; Diril MK; Renck Nunes P; Tzelepis K; Lacroix A; van Hul N; Deng LW; Matos J; Dreesen O; Bisteau X; Kaldis P
Oncogene; 2019 Feb; 38(7):998-1018. PubMed ID: 30190546
[TBL] [Abstract][Full Text] [Related]
15. Regulation of G2/M Transition by Inhibition of WEE1 and PKMYT1 Kinases.
Schmidt M; Rohe A; Platzer C; Najjar A; Erdmann F; Sippl W
Molecules; 2017 Nov; 22(12):. PubMed ID: 29168755
[TBL] [Abstract][Full Text] [Related]
16. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1.
Aarts M; Sharpe R; Garcia-Murillas I; Gevensleben H; Hurd MS; Shumway SD; Toniatti C; Ashworth A; Turner NC
Cancer Discov; 2012 Jun; 2(6):524-39. PubMed ID: 22628408
[TBL] [Abstract][Full Text] [Related]
17. Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways.
Aarts M; Bajrami I; Herrera-Abreu MT; Elliott R; Brough R; Ashworth A; Lord CJ; Turner NC
Mol Cancer Ther; 2015 Apr; 14(4):865-76. PubMed ID: 25673822
[TBL] [Abstract][Full Text] [Related]
18. Cdk1-dependent regulation of the mitotic inhibitor Wee1.
Harvey SL; Charlet A; Haas W; Gygi SP; Kellogg DR
Cell; 2005 Aug; 122(3):407-20. PubMed ID: 16096060
[TBL] [Abstract][Full Text] [Related]
19. A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase.
Sakurikar N; Thompson R; Montano R; Eastman A
Oncotarget; 2016 Jan; 7(2):1380-94. PubMed ID: 26595527
[TBL] [Abstract][Full Text] [Related]
20. Wee1 Kinase: A Potential Target to Overcome Tumor Resistance to Therapy.
Esposito F; Giuffrida R; Raciti G; Puglisi C; Forte S
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
